The group, known as MedPAC, is independent and advises Congress on Medicare. It has routinely highlighted overpayments to Medicare Advantage insurers. And it is now facing more pushback from industry ...
Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more
Medical groups affiliated with telehealth companies the FDA warned about marketing of compounded weight loss drugs may be under the microscope, too ...
A new analysis of Medicare data shows mental health specialists who embraced telehealth did not see substantially more rural patients ...
Keeping America’s lead in biotech depends on fixing what's broken about the policy status quo — and not breaking what works, ...
An unexpected discovery may bring scientists closer to a long-sought goal: finding an ideal immunotherapy target for solid tumors.
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
Scientists are often encouraged to avoid politics. But this advice is outdated, if it was ever correct in the first place,” writes Jenna Norton, NIH whistleblower.
For advocates who have been pushing to create a federal office of men's health, this could finally be the moment.
The FDA is targeting telehealth marketing of GLP-1 drugs. But those companies may not be the only ones under the microscope.
BIO's Crowley warns U.S. risks losing lead, a familiar red flag with Aldeyra, and other biotech news from The Readout ...
Welcome back! Aldeyra Therapeutics is complaining about short sellers in the run-up to an FDA approval decision. The Vertex era of frictionless commerce is coming to an end. And with Doug Ingram’s ...
The doctors behind the telehealth GLP-1 boom, a men's health office moment, and other health news ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results